Skip to content

Lot

VER-202608-174

Purity

99.74%

CJC-1295 D·2 mgRESEARCH USE ONLY
Form
Lyophilised powder
Storage
−20 °C, desiccated
Stability
24 months
CAS
863288-34-0
Formula
C165H269N47O46
Molecular weight
3647.15 g/mol
Solubility
Bacteriostatic water or 0.9% NaCl, ≥2 mg/mL

CJC-1295 DAC

GHRH(1-29) analogue with drug affinity complex

£58
Vial massCJC1295DAC-2-VER
1

119 vials in stock · dispatched within 24 h

A tetrasubstituted GHRH(1-29) analogue bearing a maleimidoproprionic acid linker for covalent serum albumin conjugation. The DAC modification is the object of substantial pharmacokinetic literature.

Albumin-binding kineticsHalf-life modelling

Supplied for laboratory research use only. Not for human or veterinary use, consumption, or clinical application.

Analysis

Certificate of analysis

RP-HPLC chromatogramColmaric Analyticals
8.51 · 99.74%9.40 · 0.24%02468101214
Retention time (min)λ 214 nm
Purity99.74%

Specification ≥ 98.0%

Lot
VER-202608-174
Released
2026-08-24
Mass expected
3647.15 Da
Mass found
3647.11 Da
Water (KF)
2.22%
Endotoxin
0.083 EU/mg
Appearance
White lyophilisate
Signed COA · CJC-1295 DAC VER-202608-174PDF ↓

Primary structure

30 residues

Hover a residue for detail

Formula
C165H269N47O46
Molecular weight
3647.15 g/mol

Interactive

Reconstitution

Vial mass

mL
mcg

Syringe

05010025.0u
Draw to
25.0 units
Volume
0.250 mL
Concentration
1.00 mg/mL
Draws per vial
8

Arithmetic for CJC-1295 DAC at the values you entered. Not a protocol and not a dose recommendation. Research use only.

Handling

On arrival
Transfer to −20 °C within two hours. Vials ship on phase-change packs rated for 72 hours.
Reconstitution
Bacteriostatic water or 0.9% NaCl, ≥2 mg/mL
After reconstitution
2–8 °C, use within 28 days. Aliquot to avoid freeze-thaw cycling.
Shelf life
24 months lyophilised, desiccated and protected from light.